U.S. Biotech Industry Analysis
UpdatedJul 27, 2024
DataAggregated Company Financials
Companies564
- 7D4.2%
- 3M16.0%
- 1Y15.7%
- YTD9.8%
In the last week, the Biotech industry is up 4.2%, with AbbVie up 7.5%. In the same time, Biogen was down 6.7%. In the last 12 months, the industry was up 16%. Looking forward, earnings are forecast to grow by 26% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 27 Jul 2024 | US$1.2t | US$164.9b | -US$28,965,808,648.76 | 26.4x | -42.6x | 7.5x |
| Mon, 24 Jun 2024 | US$1.2t | US$164.4b | -US$27,942,490,934.12 | 28.1x | -41.4x | 7x |
| Wed, 22 May 2024 | US$1.1t | US$164.6b | -US$26,765,333,205.64 | 24.5x | -42.8x | 7x |
| Fri, 19 Apr 2024 | US$1.1t | US$164.2b | -US$23,337,120,518.73 | 20.4x | -45.9x | 6.5x |
| Sun, 17 Mar 2024 | US$1.2t | US$167.4b | -US$22,071,849,383.64 | 13.9x | -53.2x | 7x |
| Tue, 13 Feb 2024 | US$1.2t | US$169.3b | -US$26,222,327,301.15 | 20.4x | -44.5x | 6.9x |
| Thu, 11 Jan 2024 | US$1.4t | US$204.8b | -US$22,494,732,823.00 | 19.3x | -64.2x | 7.1x |
| Sat, 09 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,414,218.00 | 18.7x | -58.4x | 6.3x |
| Mon, 06 Nov 2023 | US$1.2t | US$206.7b | -US$20,529,146,956.00 | 18.8x | -60.5x | 6x |
| Wed, 04 Oct 2023 | US$1.2t | US$207.3b | -US$13,085,561,707.00 | 16.6x | -94.9x | 6x |
| Fri, 01 Sep 2023 | US$1.3t | US$207.6b | -US$12,418,173,316.00 | 17.4x | -103.3x | 6.2x |
| Sun, 30 Jul 2023 | US$1.1t | US$186.0b | -US$15,177,418,533.00 | 14.7x | -74.9x | 6.1x |
| Tue, 27 Jun 2023 | US$1.1t | US$186.2b | -US$16,151,917,994.00 | 13.4x | -69.8x | 6.1x |
| Thu, 25 May 2023 | US$1.1t | US$185.9b | -US$15,950,003,280.00 | 11.5x | -71.8x | 6.2x |
| Sat, 22 Apr 2023 | US$1.2t | US$198.4b | -US$3,214,788,122.00 | 13.9x | -370.1x | 6x |
| Mon, 20 Mar 2023 | US$1.1t | US$199.2b | -US$3,870,392,033.00 | 13.2x | -288.7x | 5.6x |
| Wed, 15 Feb 2023 | US$1.2t | US$202.8b | -US$166,103,827.00 | 16.3x | -6973.2x | 5.7x |
| Fri, 13 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 658.8x | 5.8x |
| Sun, 11 Dec 2022 | US$1.1t | US$202.7b | US$1.4b | 14.6x | 811.7x | 5.6x |
| Tue, 08 Nov 2022 | US$1.1t | US$204.5b | US$3.9b | 14.4x | 280.2x | 5.3x |
| Thu, 06 Oct 2022 | US$1.1t | US$206.3b | US$5.5b | 15.3x | 193.7x | 5.2x |
| Sat, 03 Sep 2022 | US$1.0t | US$206.4b | US$6.2b | 14.6x | 168.2x | 5x |
| Mon, 01 Aug 2022 | US$1.1t | US$212.0b | US$11.3b | 15.6x | 93.2x | 5x |
| Wed, 29 Jun 2022 | US$1.0t | US$212.3b | US$11.0b | 15.6x | 94.1x | 4.9x |
| Fri, 27 May 2022 | US$1.0t | US$212.6b | US$11.1b | 15.4x | 90.6x | 4.7x |
| Sun, 24 Apr 2022 | US$1.2t | US$226.6b | US$14.7b | 17.8x | 81.5x | 5.3x |
| Tue, 22 Mar 2022 | US$1.3t | US$221.9b | US$10.6b | 19.5x | 120.4x | 5.8x |
| Thu, 17 Feb 2022 | US$1.3t | US$216.3b | US$5.9b | 22.3x | 213x | 5.8x |
| Sat, 15 Jan 2022 | US$1.3t | US$212.1b | US$2.7b | 24.4x | 482.6x | 6.2x |
| Mon, 13 Dec 2021 | US$1.4t | US$212.0b | US$3.2b | 25x | 442.4x | 6.6x |
| Wed, 10 Nov 2021 | US$1.5t | US$204.7b | US$843.8m | 26.3x | 1759.5x | 7.3x |
| Fri, 08 Oct 2021 | US$1.5t | US$196.3b | -US$2,599,455,696.00 | 23.7x | -564.3x | 7.5x |
| Sun, 05 Sep 2021 | US$1.6t | US$197.0b | -US$1,737,879,785.58 | 22.4x | -927.5x | 8.2x |
| Tue, 03 Aug 2021 | US$1.5t | US$197.0b | -US$1,424,156,187.58 | 24.2x | -1083.7x | 7.8x |
Price to Earnings Ratio
-1083.7x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.5x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.64% | |
| Healthcare | 1.23% | |
| Biotech | 4.17% | |
| Biotech | 4.17% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$185.16 | 7.5% +US$22.7b | 22.7% | PE61.7x | |
| GILD Gilead Sciences | US$77.01 | 6.1% +US$5.5b | 0.2% | PE197.8x | |
| SMMT Summit Therapeutics | US$11.55 | 31.5% +US$1.9b | 444.8% | PB183.4x | |
| AMGN Amgen | US$334.85 | 1.1% +US$1.9b | 41.7% | PE47.7x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x |
